Search
Metocurine iodide
go.drugbank.com/drugs/DB00416ApprovedWithdrawnMetocurine Iodide is no longer available on the US market. … It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine
Dornase alfa
go.drugbank.com/drugs/DB00003ApprovedInvestigationalDornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. … In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections.
Products: PULMOZYME 2.500 E./2,5 ml - Lösung für einen VerneblerIsosulfan blue
go.drugbank.com/drugs/DB09136ApprovedInvestigationalCategories: Compounds used in a research, industrial, or household settingTecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigational[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. … [L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022.
Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigationalresults in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. … , and improvements in CF symptoms.
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigationalS1P receptors are membrane-derived lysophospholipid signaling molecules that are involved in the sequestration of circulating peripheral lymphocytes in lymph nodes. … [A261826] Therefore, S1P receptor modulators like etrasimod were investigated in treating immune-mediated diseases like ulcerative colitis where a high level of inflammatory T cells is present in the gastrointestinal
Debrisoquine
go.drugbank.com/drugs/DB04840ApprovedAn adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme.
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalEfgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … and a reduction in electrical nerve impulses.
Ulipristal
go.drugbank.com/drugs/DB08867ApprovedInvestigationaldebated due to ethical concerns related to abortion (Rosato et al, 2016). … A recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily
Fluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].